About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
IP: Andreea Ciudin Mihai Collaborators: Oscar González López, Fiorella Ximena Palmas Candia, Marina Giralt Arnaiz, Marta Comas Martínez, Rosa Burgos Peláez, Irene Hernández Hernández, Enzamaría Fidilio Meli, Efráin Santiago Cordero Vázquez, Cristina Gamez Cenzano Funding agency: Instituto de Salud Carlos III Funding: 123420 Reference: PI20/01086 Duration: 01/01/2021 - 31/12/2024
IP: Concepció Jacobs Cachá Collaborators: - Funding agency: Fundació La Marató de TV3 Funding: 199966.31 Reference: 202017/10 Duration: 30/03/2021 - 31/12/2024
IP: Ibane Abasolo Olaortua Collaborators: Joaquin Seras Franzoso, Guillem Pintos Morell, Zamira Vanessa Diaz Riascos, Simon Schwartz Navarro Funding agency: EUROPEAN COMMISSION Funding: 457250 Reference: MIMIC-KEY_H2020-FETPROACT-2020 Duration: 01/06/2021 - 31/05/2025
IP: Ibane Abasolo Olaortua Collaborators: - Funding agency: Agence Nationale de la Recherche Funding: 0.01 Reference: EVERETT_ANR-BIOPNSE2020 Duration: 01/11/2022 - 31/10/2025
PMID: 38075176 Journal: Advances in Laboratory Medicine Year: 2023 Reference: Adv Lab Med. 2023 Sep 13;4(3):203-204. doi: 10.1515/almed-2023-0116. eCollection 2023 Sep. Impact factor: Publication type: Editorail in international publication Authors: Arribas, Ignacio; Fernandez-Calle, Pilar; Ferrer-Costa, Roser; Gonzalez, Alvaro; Jimenez, Wladimiro et al. DOI: 10.1515/almed-2023-0116
PMID: 38075162 Journal: Advances in Laboratory Medicine Year: 2023 Reference: Adv Lab Med. 2023 Sep 8;4(3):205-206. doi: 10.1515/almed-2023-0113. eCollection 2023 Sep. Impact factor: Publication type: Editorial in national publication Authors: Arribas, Ignacio; Fernandez-Calle, Pilar; Ferrer-Costa, Roser; Gonzalez, Alvaro; Jimenez, Wladimiro et al. DOI: 10.1515/almed-2023-0113
PMID: 38097770 Journal: Communications medicine Year: 2023 Reference: Commun Med (Lond). 2023 Dec 14;3(1):182. doi: 10.1038/s43856-023-00420-8. Impact factor: Publication type: Paper in international publication Authors: Araujo, Silvia G; Buti, Maria; Fernandez, Emma; Forns, Xavier; Lazarus, Jeffrey V; Lens, Sabela; MacKinnon, Marina; Martro, Elisa; Nomah, Daniel K; Nunez, Carmen Lopez et al. DOI: 10.1038/s43856-023-00420-8
PMID: 38111084 Journal: LIVER INTERNATIONAL Year: 2023 Reference: Liver Int. 2023 Dec 18. doi: 10.1111/liv.15814. Impact factor: Publication type: Paper in international publication Authors: Barreira-Diaz, Ana; Buti, Maria; Esteban, Rafael; Feliu-Prius, Anna; Palom, Adriana; Rando, Ariadna; Riveiro-Barciela, Mar; Rodriguez-Frias, Francisco; Ruiz-Cobo, Juan C; Vargas-Accarino, Elena et al. DOI: 10.1111/liv.15814
The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.
In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.
During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.
